Clinical Trials

Expanded Access Policy

ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. The goal of our current clinical study program is to enroll patients and obtain clinical data on evorpacept that is required by the U.S. Food and Drug Administration (FDA) and other regulatory authorities for review and approval of marketing applications for this investigational agent.

We believe that focusing on clinical studies is the most appropriate way to achieve this goal; therefore, we do not currently offer access to evorpacept outside of clinical studies and, at this time, we have no Expanded Access Program (sometimes referred to as "compassionate use" or "pre-approval access").
 
If you have additional questions regarding this policy, please speak with your healthcare provider or contact: medinfo@alxoncology.com.